Axsome's stable $800M+ revenue base caps downside and supports ongoing operations, shifting risk from existential to executional and enabling pipeline-driven upside. Auvelity (for major depressive disorder) is the big draw with sales up 69% in Q3, with management thinking peak sales could be $2 billion or so, about four times current run-rate basis. Two drugs are likely to get FDA approval in 2026: AXS-12 targeting narcolepsy ($500 million opportunity) and AXS-05 for Alzheimer's agitation with potential into the $1.5 billion range or more (approval likely in first half of 2026).
Cyborg Score Rationale
Sales growth is rapid (up 63% and 72% the past two quarters), with analysts looking for 50%-plus gains all of next year. Multiple commercial products and late-stage pipeline catalysts position Axsome for significant value creation, though company remains unprofitable as it executes on growth.
Top Insights
Sunosi is showing solid growth for sleep apnea (sales up 35% last quarter) with recent launch of Symbravo for acute migraines.
Axsome has another drug in Phase III trials (for ADHD and other indications) that it thinks can be another $1 billion producer.
Revenue base of $800M+ caps downside; however, incremental SG&A must remain below 40% of incremental revenue to maintain operating leverage.
Multiple analyst price targets raised significantly in early 2026 (UBS raised to $248, Needham to $225, H.C. Wainwright to $200), demonstrating strong institutional confidence.
Named Competitors
Cymbalta — Depression and anxiety treatment
Lexapro — Selective serotonin reuptake inhibitor for depression
Modafinil — Wakefulness-promoting agent for narcolepsy
Lyrica — Fibromyalgia and neuropathic pain treatment
Recent Developments
(January 2026) Axsome initiates FORWARD Phase 3 trial of AXS-14 for fibromyalgia management
(January 2026) FDA accepts priority review of AXS-05 sNDA for Alzheimer's disease agitation
(January 2026) AXS-12 NDA submission on track with narcolepsy data being presented at conferences
(December 2025) Full year 2025 net product revenue of $638.5 million, up 66% year-over-year
Open the full interactive Axsome Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.